Date
May 17, 2022
Place
Milan
The Commission on Life Science 2022 - The Winners
The Commission on Life Science met on May 16 2022 to decide the winning startup proposal for the sector.
The commission chose among ten finalists pre-selected by UniCredit Start Lab team. The Commission was composed of senior executives from leading Italian companies such as:
- Rosario Bifulco, Sole Director, Bootes
- Maurizio Colombo, Vice Chairman, Sapio
- Fabrizio Conicella, CEO, Life Science District
- Marco Ferrari, CEO, Anemocyte
- Luca Foresti, CEO, Centro Medico Santagostino
- Enrica Mambelli, CFO, Althea
- Giovanni Mattoni, Head of Global Biotech Engineering, Merck Group
- Alessandro Porcu, CEO Openzone and Board Member Zcube, Zambon Group
The winning startup of the first prize for the Life Science sector is Moveo - based in Padua - which has developed a self-powered, extremely lightweight soft exosuit to augment walking by people with limited mobility, named ExoBand. ExoBand is designed for those whose walking ability has been affected by degenerative disease, age or injury, allowing them to walk further with less energy expenditure.
The winning startup will receive a 10.000 € grant.
The Commission awarded the second prize to AorticLab - from Turin - which aims to innovate and improve the treatment of patients suffering from aortic valve stenosis. It is currently developing a safe and low invasive system for the functional restoration of the native aortic valve affected by calcific dystrophy.
The third prize went to Dorian Technologies - from Genoa - which provides easy access to the most advanced quantitative-imaging techniques based on radiomics and AI in the medical field. By leveraging cloud computing, the platform transforms any customer device into an advanced imaging laboratory, cutting down time and diagnostic error.
Finally, a special mention went to D-Tails - based in Rome - which researches and develops methods for the early diagnosis of Alzheimer's disease (by monitoring specific protein aggregates through retinal observation) and for the mass screening of breast and prostate cancer (technique derived from C.elegans receptors that shows repetitive and specific behaviour when exposed to patients' urine with 99% accuracy).
To read more about all ten of the 2022 UniCredit Start Lab finalists in the Life Science category, please click here.